Copyright 2016 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
To the Editor Does clozapine offer additional therapeutic benefit to patients who have received inadequate therapeutic benefit from other antipsychotic medications (APMs)? This is the question Samara et al1 aimed to address in their article in JAMA Psychiatry.
When Kane et al2 undertook the comparison of clozapine and chlorpromazine, “inadequate therapeutic benefit” was straightforward: tens of thousands of patients were state-hospitalized in the long-term because they were profoundly psychotic, violent, and/or self-injurious. In 268 of them whose condition did not improve during a high-dose haloperidol lead-in, clozapine handily beat chlorpromazine on psychopathology change. Those of us working in state hospitals as clozapine became available for clinical use noted that the hospitals became less dangerous and then less populous.
McEvoy JP. Use of Clozapine in Schizophrenia. JAMA Psychiatry. 2016;73(10):1097–1098. doi:10.1001/jamapsychiatry.2016.1241
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: